Gains

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">In a volatile trading session on Friday, major stocks in the consumer goods and healthcare sectors showed significant movements, driven by earnings reports, strategic partnerships, and legal settlements. Nike (NYSE: NKE), Humana (NYSE: HUM), and UnitedHealth Group Incorporated (NYSE: UNH) all garnered investor attention for various reasons.</p>
<h3 id="nike-shares-plummets-after-weak-forecast">Nike Shares Plummets After Weak Forecast</h3>
<p>Nike shares <a href="https://tokenist.com/nike-stumbles-as-gloomy-forecast-sends-shares-sprinting-downward/" rel="noopener noreferrer nofollow" class="deco-link">plummeted</a> 19.54% to $75.78, wiping out nearly $28 billion in market value. The sportswear giant reported mixed fourth-quarter results, with earnings beating expectations at $1.01 per share but revenue falling short at $12.61 billion, down 2% year-over-year. Despite a 5% increase in wholesale revenue, direct-to-consumer sales declined 8%.<br><br>Nike’s gloomy forecast for fiscal 2025, projecting a 10% sales drop in Q1 and mid-single-digit declines for the full year, spooked investors. The company cited slower online sales, planned reductions in classic footwear lines, uncertainty in China, and uneven consumer trends as contributing factors.<br><br>With a market cap of $114.402 billion and a P/E ratio of 27.70, Nike’s stock has significantly underperformed <a href="https://tokenist.com/investing/spx-vs-spy/" class="deco-link" rel="noopener noreferrer nofollow">the S&amp;P 500</a> this year, down 29.66% year-to-date.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="humana-stock-gains-on-pyschamor-collaboration">Humana Stock Gains on PyschAmor Collaboration</h3>
<p>Humana shares bucked the trend, rising 3.97% to $376.45. The health insurance provider announced a collaboration between its subsidiaries, Conviva Care Center and CenterWell Senior Primary Care, and PsychArmor, a leading provider of military cultural awareness training. <br><br>This partnership will give 23 senior primary care centers in Texas access to the Veteran Ready Healthcare Certificate program, which aims to improve care for aging veterans and their families.<br><br>The initiative covers training in military culture, communication with veterans, suicide prevention, and opioid use disorder. As of March 31, 2024, Humana’s CenterWell and Conviva provided care to about 318,000 seniors across 300 centers in 15 states.<br><br>With a market cap of $45.363 billion and a <a href="https://tokenist.com/investing/p-e-ratio/" rel="noopener noreferrer nofollow" class="deco-link">P/E ratio</a> of 22.35, Humana’s stock has underperformed the S&amp;P 500 year-to-date but shows a positive 5-year return of 47.15%.</p>
<h3 id="unitedhealth-group-s-optumrx-settles-opioid-prescriptions-case-shares-gain">UnitedHealth Group’s OptumRx Settles Opioid Prescriptions Case, Shares Gain</h3>
<p>UnitedHealth Group (UNH) shares climbed 2.49% to $498.55 after news of a <a aria-label="$20 million settlement (opens in a new tab)" href="https://www.justice.gov/opa/pr/optumrx-agrees-pay-20m-resolve-allegations-it-filled-certain-opioid-prescriptions-violation" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">$20 million settlement</a> by its pharmacy benefit manager unit, OptumRx. The settlement addresses U.S. government claims that OptumRx improperly filled certain opioid prescriptions between 2013 and 2015.<br><br>This marks the first government agreement with a pharmacy benefit manager over alleged illicit opioid prescriptions. The broader opioid litigation has resulted in nearly $50 billion in settlements across the healthcare industry.<br><br>UnitedHealth Group, with a market cap of $458.775 billion and a P/E ratio of 29.70, has shown resilience with a positive 1-year return of 4.90% and an impressive 5-year return of 118.03%.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/stocks-to-watch-today-nike-humana-and-unitedhealth-incorporated/">Stocks to Watch Today: Nike, Humana, and UnitedHealth Incorporated</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Stocks to Watch Today: Nike, Humana, and UnitedHealth Incorporated

Indice dei contenuti

Tokenist

Altri articoli pubblicati su 28 giu 2024

Bitcoin Miner Selling Cools Off – Is This The Breakout Moment?

The purpose and functionality of exchange coins and tokens

Solana’s Decentralization and Demand: Key Factors in Spot ETF Approval

Bitcoin Miners May Be Done Selling: Here's What That Means

Enjoy Early Rewards Now with Qubetics Whitelist While Ethereum and Cardano Grapple with Major Hur...

Notcoin and Blastup Investors Join MoonBag’s Top Crypto Presale in 2024 as Stage 6 is Ending Soon...

Iscriviti alla nostra newsletter gratuita per aggiornamenti giornalieri sulle criptovalute!